In this blog I want to highlight some critical updates from the General Pharmaceutical Council (GPhC) that every pharmacy professional—whether you’re a pharmacist, technician, or pharmacy owner—should be aware of. These issues have prompted serious regulatory concerns and demand thoughtful consideration and action where appropriate.
Risk Assessments are a regulatory requirement in medicines wholesaling but have you considered that they could also be very useful in pharmacy practice?
The MHRA have updated their Blue Guide on Advertising and Promoting Medicines. The update is to Appendix 4 with new Best Practice guidance on the sale of medicines for pain relief.
Unless they appear on the NIMAR list, PLGB licensed medicines are not licensed in Northern Ireland. That means they are effectively supplied to NI as an Unlicensed ‘Special’.
After the implementation of the Windsor Framework, the Medicines and Healthcare products Regulatory Agency (MHRA) will license all medicines across the whole of the UK’.
